相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Middle East Respiratory Syndrome
Yaseen M. Arabi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome
Uh Jin Kim et al.
ANTIVIRAL THERAPY (2016)
PubMed-cited research articles on the Middle East respiratory syndrome
Yaseen Arabi et al.
ANNALS OF THORACIC MEDICINE (2016)
A review of treatment modalities for Middle East Respiratory Syndrome
Yin Mo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Non-randomised Ebola trials-lessons for optimal outbreak research
Giuseppe Ippolito et al.
LANCET INFECTIOUS DISEASES (2016)
Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity
Chan-Ki Min et al.
SCIENTIFIC REPORTS (2016)
Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients
Ghaleb A. Almekhlafi et al.
CRITICAL CARE (2016)
IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study
Sarah Shalhoub et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
Jasper Fuk-Woo Chan et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials
Xiaojie Huang et al.
SCIENTIFIC REPORTS (2015)
Ribavirin and interferon-alpha 2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases
Mohammed Khalid et al.
ANTIVIRAL THERAPY (2015)
Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen
Nikolaos Spanakis et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study
Jaffar A. Al-Tawfiq et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2014)
Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
Brit J. Hart et al.
JOURNAL OF GENERAL VIROLOGY (2014)
Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
Ali S. Omrani et al.
LANCET INFECTIOUS DISEASES (2014)
Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?
Emmanuel Faure et al.
PLOS ONE (2014)
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
An-Wen Chan et al.
ANNALS OF INTERNAL MEDICINE (2013)
Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus
Peter A. Banks et al.
GUT (2013)
MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment
Adriaan H. de Wilde et al.
JOURNAL OF GENERAL VIROLOGY (2013)
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
Jasper F. W. Chan et al.
JOURNAL OF INFECTION (2013)
Human Cell Tropism and Innate Immune System Interactions of Human Respiratory Coronavirus EMC Compared to Those of Severe Acute Respiratory Syndrome Coronavirus
Florian Zielecki et al.
JOURNAL OF VIROLOGY (2013)
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques
Darryl Falzarano et al.
NATURE MEDICINE (2013)
Inhibition of novel β coronavirus replication by a combination of interferon- α2b and ribavirin
Darryl Falzarano et al.
SCIENTIFIC REPORTS (2013)
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Ali Moh Zaki et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Conducting Research in Disease Outbreaks
Ruth Macklin et al.
PLOS NEGLECTED TROPICAL DISEASES (2009)
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 μg QOD in patients with relapsing-remitting multiple sclerosis:: A multicenter, randomized, double-blind, parallel-group pilot study
Barrie J. Hurwitz et al.
CLINICAL THERAPEUTICS (2008)
Interferon beta-1b (Betaseron (R)/Betaferon (R)) is well tolerated at a dose of 500 mu g: interferon dose escalation assessment of safety (IDEAS)
MH Gottesman et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
CM Chu et al.
THORAX (2004)
Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group
R Bellomo et al.
CRITICAL CARE (2004)
Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections
H Schäfer et al.
STATISTICS IN MEDICINE (2001)
分享论文
